Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 10
Submit an article Journal homepage
145
Views
8
CrossRef citations to date
0
Altmetric
Letters to the Editor

The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial

Heather E. Eve Department of Haematology, Derriford Hospital, Plymouth, Devon, UK
,
Jo Gambell Cancer Research UK and UCL Cancer Trials Centre, London, UK
,
Paul Smith Cancer Research UK and UCL Cancer Trials Centre, London, UK
,
Wendi Qian Cancer Research UK and UCL Cancer Trials Centre, London, UK
&
Simon A. J. Rule Department of Haematology, Derriford Hospital, Plymouth, Devon, UKCorrespondence[email protected]
Pages 1709-1711 | Received 01 Jun 2009, Accepted 14 Jul 2009, Published online: 08 Oct 2009

References

  • A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994
  • Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565
  • Hoster E, Dreyling M, Unterhalt M. Statistical power and validation of the MIPI. Blood 2008; 112: 2583–2584
  • Terol M J, Teruel A I, Amat P, et al. Validation of the new prognostic index (MIPI) in mantle cell lymphoma: a single institution experience [abstract]. Ann Oncol 2008; 19(4)439
  • Salek D, Vasova I, Pytlik R, et al. Mantle cell lymphoma international prognostic score is valid and confirmed in unselected cohort of patients treated in rituximab era [abstract]. Blood 2008; 112: 3745
  • Pan L, Guthrie K A, Till B G, et al. The mantle cell lymphoma international prognostic index (MIPI) at diagnosis is associated with survival of mantle cell lymphoma patients undergoing autologous hematopoietic stem cell transplantation [abstract]. Blood 2008; 112: 1143
  • Shah J J, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008; 112: 2583
  • Romaguera J E, Fayad L, Rodriguez M A, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.